The Microphthalmia-associated transcription factor (Mitf) is an essential basic helix-loop-helix leucine zipper transcription factor for mast cell development. Mice deficient in Mitf harbor a severe mast cell deficiency, and Mitf-mutant mast cells cultured ex vivo display a number of functional defects. Therefore, an understanding of the genetic program regulated by Mitf may provide important insights into mast cell differentiation. Multiple, distinct isoforms of Mitf have been identified in a variety of cell types; we found that Mitf-a, Mitf-e, and Mitf-mc were the major isoforms expressed in mast cells. To determine the physiologic function of Mitf in mast cells, we restored expression of these isoforms in primary mast cells from Mitf ؊/؊ mice. We found that these isoforms restored granular morphology and integrin-mediated migration. By microarray analysis, proteases, signaling molecules, cell surface receptor, and transporters comprised the largest groups of genes up-regulated by all isoforms. Furthermore, we found that isoforms also regulated distinct genes sets, suggesting separable biological activities. This work defines the transcriptome regulated by Mitf in mast cells and supports its role as master regulator of mast cell differentiation. Expression of multiple isoforms of this transcription factor may provide for redundancy of biological activities while also allowing diversity of function. (2), congestive heart failure (3), and multiple sclerosis (4). Although mast cells have the capacity to promote diverse pathologic states, they also participate in normal physiologic processes, such as innate immunity against parasitic and bacterial infections (5, 6). These diverse functions may be regulated by distinct and shared pathways. A dissection of these pathways may allow selective regulation of these processes for therapeutic benefit.
M ast cells are central effectors of allergic and hypersensitivity reactions (1) . Mast cells have also been implicated in the pathogenesis of a variety of other diseases such as rheumatoid arthritis (2) , congestive heart failure (3), and multiple sclerosis (4) . Although mast cells have the capacity to promote diverse pathologic states, they also participate in normal physiologic processes, such as innate immunity against parasitic and bacterial infections (5, 6) . These diverse functions may be regulated by distinct and shared pathways. A dissection of these pathways may allow selective regulation of these processes for therapeutic benefit.
A number of transcription factors play essential roles in mast cell development, including the zinc finger factors GATA-1 (7) and GATA-2 (8), the Ets family member PU.1 (9) , and the helixloop-helix leucine zipper factor, Microphthalmia-associated transcription factor (Mitf) 4 (10, 11) . These factors regulate sets of genes, or transcriptomes, essential for the genetic program of differentiation and function of the mast cell. The central role that Mitf plays in mast cell development is clearly demonstrated by the phenotype of mice with mutations in Mitf. Mitf mutant mice are deficient in the mast cells that populate the skin and peritoneum; furthermore, primary mast cells cultured from these animals harbor a number of functional defects ex vivo. In addition, Mitf mutant mast cells are deficient in a number of genes that encode for proteins that participate in biologically important processes, including proteases (12) (13) (14) (15) , adhesion molecules (16, 17) , metabolic enzymes (15, 18, 19) , and growth factor receptors (20, 21) . Thus, a comprehensive understanding of the gene program regulated by Mitf in mast cells, or the Mitf transcriptome, can lead to important insights into mast cell biology. To date, nine distinct isoforms of Mitf have been identified (22) . These isoforms arise from an alternative splicing event that joins a unique first exon with the common body of the gene. The resulting proteins possess distinct amino termini, but share transactivation, DNA binding, and dimerization motifs. The expression of alternatively spliced transcripts may be controlled by distinct promoter/ enhancer elements, allowing for differential regulation of isoforms. Furthermore, transcripts that encode for unique proteins species may possess distinct biological functions. Alternative splicing of mRNA transcripts is a widespread mechanism for generating diversity in multicellular organisms. Thirty-five to 65% of human genes are predicted to undergo alternative splicing, the majority of which encode for distinct protein species (23) . This mechanism is particularly widespread in complex systems such as the immune system (24) . The genomic organization of the Mitf locus allows for highly regulated, tissue-selective expression of each isoform. However, cell-restricted isoforms may also exhibit distinct functions, a feature that may further expand the functional diversity of the Mitf gene.
Mitf is essential for the development of a diverse array of tissue types other than mast cells, including osteoclasts, melanocytes, and retinal pigmented epithelium. Two Mitf isoforms have been shown to display a cell-restricted pattern of expression (22) : the Mitf-mc (25) isoform identified in mast cells and the Mitf-m (26, 27) isoform expressed in melanocytes. These isoforms possess identical functional domains including the transactivation, the DNA-binding basic domain, and the helix-loop-helix leucine zipper dimerization domain. They differ only by the presence of unique aminoterminal domains. Despite these shared motifs, we have previously shown that these two isoforms display a differential capacity to transactivate gene targets in reporter assays (25) . This finding suggests that Mif isoforms may regulate distinct gene targets in vivo.
Prior studies have identified several important Mitf gene targets by comparing wild-type mast cells to either Mitf null or Mitf dominant-negative mast cells. The expression of some of these genes are selectively impaired in the Mitf dominant-negative and not in Mitf null mast cells, a finding that suggests that the genes reported in these studies may also be regulated by factors other than Mitf. None of these studies have examined the shared and differentially expressed gene targets of the physiologically expressed Mitf isoforms in mast cells. A comprehensive examination of the transcriptome of the in vivo-expressed Mitf isoforms in mast cells has not been reported and may provide important knowledge about the true biologic function of Mitf. Thus, the aim of this study was to investigate the role of Mitf isoforms in mast cell development. To address this question, we first determined the Mitf isoforms expressed in mast cells. We then restored the expression of the mast cell-expressed Mitf isoforms into Mitf Ϫ/Ϫ primary mast cells and examined their capacity to restore Mitf-dependent function. We determined the transcriptome of these Mitf isoforms by microarray analysis, and identified the common and distinct gene sets that they FIGURE 1. Mitf isoform expression in mast cells. A, RT-PCR analysis of in vitro-differentiated mast cells from murine embryonic stem cells shows expression of the mast cell isoform (mast), e-isoform (E-form), and a-isoform (A-form). Wright-Geimsa stain of cytospin preparations from differentiated cells at weekly time points above (original magnification, ϫ60). Mast cell isoform and e-isoform expression is detectable with the appearance of morphologically identifiable mast cells at wk 3 and wk 4. B, RT-PCR analysis of specific Mitf isoforms from various tissue sources. Primary bone marrow-derived wild-type (Mitf ϩ/ϩ ) mast cells (1 o BMMC), intestinal mast cells, and the mast cell line, C57, show expression of mast cell, e-and a-isoforms. The heart isoform is also detected from intestinal cells. The melanoma cell line (B16), macrophage cell line (RAW), and heart tissue are used for controls for the heart, melanocyte, and a-isoforms. Specific isoforms are not detected from peritoneal mast cells, and no Mitf expression is detectable from Mitf Ϫ/Ϫ BMMCs. C, Schematic representation of protein domains of the Mitf isoforms expressed in mast cells show the unique amino-terminal domains of the mast cell isoform (z, 43 aa) and the a-isoform (o, 35 aa). The contiguous B-domain (u, 83 aa) is shared between mast cell and a-isoform. The e-isoform harbors a truncated B domain amino terminus (66 aa). All isoforms share the transactivation domain (TAD), as well as the DNA binding basic domain and helix-loop-helix leucine zipper dimerization motif (b-hlh-zip).
regulate. The expression of physiologically important genes were verified by quantitative PCR analysis.
Materials and Methods

Animals
The vga9 mice were provided by Dr. D. Fisher (Dana-Farber Cancer Institute, Boston, MA). These mice harbor a transgene of the vasopressin-␤ galactosidase that disrupts the 5Ј genomic locus of the Mitf gene (27) . These mice do not express Mitf at the protein and RNA level. These mice are bred on a C57BL/6 background. Four-to 8-wk-old vga9/vga9 (Mitf Ϫ/Ϫ ) mice and wild-type littermates (Mitf ϩ/ϩ ) were used to obtain splenocytes and bone marrow. Mice were maintained in the Johns Hopkins University Animal Facilities in accordance with institutional guidelines.
Cells
Murine embryonic stem cells were differentiated into mast cells according to the method described by Tsai et al. (28) with minor modifications. Briefly, strain 129v murine embryonic stem cells were grown on a feeder layer of mitomycin-treated mouse embryonic fibroblasts in DMEM (Invitrogen Life Technologies) supplemented with 15% ES grade FBS (HyClone), 1% penicillin/streptomycin and glutamine, 100 M 2-ME, 1 mM sodium pyruvate, 1% nonessential amino acids (Invitrogen Life Technologies), and 100 U/cc mouse recombinant leukemia inhibitory factor (Chemicon International). Embryonic stem cells were adapted to IMDM (Invitrogen Life Technologies) with supplements as listed above and grown on 0.2% gelatin-coated plates before differentiation. To differentiate embryonic stem cells, 5000 cells were plated on bacterial-grade petri dishes in 1.5 cc of IMDM with 0.9% methycellulose (StemCell Technologies) supplemented with 15% ES grade FBS, 1% penicillin/streptomycin and glutamine, 434 M monothioglycerol, 1 mM sodium pyruvate, 1% nonessential amino acids, with 50 ng/cc stem cell factor (SCF) and 5 ng/cc IL-11. After 1 wk, developing embryoid bodies were supplemented with culture medium containing 60 ng/cc SCF, 30 ng/cc mouse rIL-3, and 30 ng/cc IL-6. At wk 2 of culture, embryoid bodies were transferred to tissue culture flasks and allowed to differentiate in DMEM supplemented with 10% FCS, 1% penicillin/streptomycin and glutamine as well as 20% WEHI supernatant, and 50 ng/cc SCF. Bone marrow-derived mast cells (BMMC) were derived from 4-to 8-wk-old Mitf ϩ/ϩ and Mitf Ϫ/Ϫ mice. Bone marrow obtained from femurs and tibias and splenocytes obtained from spleens from these mice were cultured in DMEM with 10% FCS supplemented with 1% penicillin/streptomycin and glutamine as well as 20% WEHI supernatant and 50 ng/cc mouse recombinant SCF as described previously (25) . Peritoneal mast cells were isolated from 4-to 8-wk-old Mitf ϩ/ϩ mice. A total of 10 cc of PBS was injected into the peritoneal cavity and aspirated. The cell suspension was then layered on a 17.5% NycoPrep gradient (Axis-Shield) and centrifuged at 400 ϫ g for 20 min. The cell pellet was enriched for peritoneal mast cells and was expanded for 2 wk in DMEM supplemented with 10% FCS, 1% penicillin/streptomycin and glutamine as well as 10 ng/cc IL-3, and 50 ng/cc SCF. Intestinal mast cells were obtained as described previously (29) . Briefly, small intestines were removed from 4-to 8-wk-old Mitf ϩ/ϩ mice and flushed with 40 -50 cc of HBSS. The intestines were opened and rinsed with HBSS, finely chopped with a razor blade, and then enzymatically digested in 30 cc of RPMI 1640 (Invitrogen Life Technologies) with 10% FBS with 1 mg/cc collagenase IV (Worthington). Three enzymatic digestions were done at 37 o C with shaking for 20 min. The cell suspension was pelleted and resuspended in 44% Percoll (Sigma-Aldrich), underlayed with a 67% Percoll layer, and centrifuged at 400 ϫ g for 20 min. Cells at the interface were collected, washed, and expanded for 3 wk in DMEM supplemented with 10% FCS, 1% penicillin/streptomycin and glutamine as well as 10 ng/cc IL-3, and 50 ng/cc SCF. All cytokines were mouse recombinant products obtained from R&D Systems.
Plasmids
The pMMP-IRES-puro was constructed from the pMMP retrovirus (30) (donated by Dr. R. Mulligan, Harvard Medical School, Boston, MA). The puromycin N-acetyltransferase (streptomyces) gene that encodes puromycin resistance (599 bp) was amplified by PCR with a SmaI site engineered at the 5Ј end and an Age1 site engineered at the 3Ј end. The puromycin N-acetyltransferase PCR insert was subcloned into the SmaI/Age1 site of pIRES-EGFP (Clontech). Thus, the puromycin resistance gene was placed downstream of the IRES element. The IRES-puromycin resistance cassette (IRES-puro) was released from the pIRES-EGFP backbone with BamH1 and Age1. The overhanging ends were filled in with Klenow. The pMMP backbone was cut with BamH1, and the overhanging ends were filled in with Klenow, then dephosphorylated with calf intestinal phosphatase. The IRES-puro cassette was blunt end cloned into the pMMP backbone. Mitf isoforms were constructed by releasing the full-length cDNA of Mitf isoforms from pEBB-Mitf (25) with NcoI and inserting them into the NcoI site of pMMP-IRES-puro. These fragments contain a hemagglutinin aminoterminal tag. All constructs were verified by DNA sequencing.
Retroviral transduction of BMMCs
Retrovirus was produced by the method as described by Ory et al. (31) . The 293GPG cell line was grown in 15-cm tissue culture plates with DMEM supplemented with 10% FBS and 1% penicillin/streptomycin and glutamine and 1 g/cc doxycycline. The 293GPG cell line was transfected with 25 g of pMMP-IRES-puro-Mitf and 75 g of FuGENE 6 (Invitrogen Life Technologies). Medium was replaced daily and doxycycline was removed to induce expression of VSV-G. Supernatant was collected on days 4 -8 after transfection. Retrovirus was concentrated by centrifuging supernatant at 26,000 ϫ g in an ultracentrifuge for 1.5 h. Concentrated retrovirus was resuspended in TEN buffer overnight at 4 o C. BMMCs were cultured from bone marrow cells and splenocytes that were obtained from Mitf ϩ/ϩ mice and Mitf Ϫ/Ϫ mice as outlined above. After 1-2 wk in culture, 2 ϫ 10 6 cells per cc from Mitf Ϫ/Ϫ mice were transduced with concentrated retrovirus (100 -200 mcl) with 8 g/cc polybrene, for ϳ24 h. Retroviral transduction was repeated twice, after which cells were resuspended in fresh medium. After 2-3 days in culture, 2 g/cc puromycin was added and maintained in culture to select for stably transduced cells.
Flow cytometry
All flow cytometry was performed on the FACScan with CellQuest software (BD Biosciences). For Ab labeling, cells were washed with PBS and 2% FBS. Low-affinity Fc and -␥ receptors were first blocked with anti-CD23 Abs (B3B4; BD Pharmingen) and anti-CD16/32 (2.4G2; BD Pharmingen) at 10 g/cc for 15 min on ice. Staining for ␣ 4 integrin was done with FITC-labeled Abs to VLA4 (clone P2/2; Chemicon International) at 10 g/cc for 15 min on ice. Staining for c-Kit was done with biotin-labeled Abs (clone 2B8; BD Pharmingen) at 15 g/cc for 15 min on ice. Labeling was then done with quantum Red streptavidin (Sigma-Aldrich).
Integrin-directed migration (haptotaxis) assay
Haptotaxis assays were performed as described previously (32) . Briefly, Transwell chambers (Costar) were coated with RetroNectin (Takara). RetroNectin is a chimeric peptide of human fibronectin. Mitf ϩ/ϩ , Mitf Ϫ/Ϫ , and retrovirally transduced Mitf Ϫ/Ϫ BMMCs were removed from SCF and maintained in IL-3 for 48 h before assay. Equal numbers of cells were aliquoted in fibronectin-coated Transwell chambers. Cells were plated on BSA-coated chambers for a negative control. The chambers were immediately placed within the wells of 24-well plates containing medium with or without SCF. Plates were incubated for 4 -8 h at 37°C with 5% CO 2 . The chambers were removed and washed with PBS. Cells remaining on the inner surface of the chambers were removed using a Q-Tip. The cells that migrated to the opposite side of the plate were stained with crystal violet stain and counted using an inverted microscope at ϫ40 magnification. The total number of cells from 20 fields was counted, and the average number of cells per field was determined. Experiments were performed in triplicates and on three separate occasions.
Microarray expression profiling and data analysis
Messenger RNA was collected from Mitf ϩ/ϩ , Mitf Ϫ/Ϫ , and retrovirally transduced Mitf Ϫ/Ϫ BMMCs that were cultured in IL-3 and SCF for 8 -12 wk. The mRNA samples were submitted to Johns Hopkins Hospital Microarray core facility, and expression profiling was performed using Affymetrix MOE430A Chips. To estimate the gene expression signals, data analysis was conducted on the chips' CEL file probe signal values at the Affymetrix probe pair (perfect match probe and mismatch probe) level, using the statistical technique GCRMA (Robust Multiarray Analysis Using GC content for Background adjustment) (33, 34) with the bioconductor package gcrma available at www.bioconductor.org. This probe level data processing includes a normalization procedure using quantile normalization (35) to reduce the obscuring variation between microarrays, which might be introduced during the processes of sample preparation, manufacture, fluorescence labeling, hybridization, and/or scanning. With the signal intensities estimated above, an empirical Bayes method with the ␥-␥ modeling, as implemented in the R package EBarrays, was used to estimate the posterior probabilities of the differential expression of genes between Mitf Ϫ/Ϫ BMMCs, which were transduced with individual Mitf isoforms and Mitf Ϫ/Ϫ cells that were transduced with the vector control (36 -38) . The criterion of the posterior probability Ͼ0.5, which means the posterior odds favoring change, was used to produce the differentially expressed gene lists. All computation was performed under R environment, and all bioconductor packages are available at www.bioconductor.org. This method was also used to estimate the probabilities of differentially expressed genes between Mitf ϩ/ϩ and Mitf Ϫ/Ϫ BMMCs. The microarray experiments were performed twice on mRNA obtained from two separate retroviral transductions. Data from the two experiments were pooled to obtain the differentially expressed probe sets between Mitf isoform-expressing cells and vector-transduced cells. Probe sets that were up-regulated by Mitf isoforms compared with the vector alone were identified and annotated with the GeneSpring software (Agilent Technologies). The resulting lists of annotated genes were visually inspected, and duplicates were removed. Probe sets that were differentially regulated between Mitf ϩ/ϩ and Mitf Ϫ/Ϫ cells were also identified; genes up-regulated by Mitf isoforms that were also up-regulated in Mitf Ϫ/Ϫ cells were removed from the list. The Venn diagram analysis of overlapping and unique gene sets was performed with the GeneSpring software. Gene function was annotated visually as well as with GeneSpring software and EASE software (39) . Using the EASE software, genes were grouped based on biological function using the gene ontogeny program level 3. Unique gene lists for each of the isoforms, Mitf-mc, Mitf-e, and Mitf-a, were identified using the GeneSpring software program. These lists, which include GenBank accession number and the average fold increase of signal intensity compared with vector, can be found in the supplemental material. 5 
Quantitative real-time PCR
RNA was harvested from cells with TRIzol (Invitrogen Life Technologies), and cDNA was made with the first-strand synthesis kit (Invitrogen Life Technologies). One to 5 g of RNA was used as starting material for 5 The online version of this article contains supplemental material. synthesis. Conventional PCR for Mitf isoforms was performed with primers and conditions as described previously (25) . Real-time quantitative PCR was performed using a SYBR Green mix (Bio-Rad) on an iQ5 multicolor Real-Time PCR Detection System (Bio-Rad). Primers were optimized for temperature and were used at a concentration of 200 nM. Primer sequences and melting temperatures are as follows: ␣ E integrin sense 5Ј-AAC GGA GGG TCC TTT CTG TGT GAA and antisense 5Ј-TGG ATC  TCA GCG 
Results
Identification of Mitf isoforms expressed in mast cells
To determine the Mitf isoforms expressed in mast cells, we examined Mitf expression in mast cells derived from several tissue sources by RT-PCR (Fig. 1, A and B) . We found that three Mitf isoforms were predominantly expressed in mast cells: the mast cell isoform (Mitf-mc), the e-isoform (Mitf-e), and the a-isoform (Mitf-a). These isoforms were strongly expressed in primary BMMC, in vitro-differentiated mast cells from murine embryonic stem cells, and mast cells derived from the small intestine. We previously identified Mitf-mc from mast cells (25) and its expression has been shown to be mast cell-specific (22) . Mitf-e was also originally identified from mast cells (41) and is highly expressed in mast cells, but also in other selected cell types (22) . The Mitf-a isoform is widely expressed in many tissues. Using the in vitro mast cell differentiation system, we found that Mitf-e and Mitf-mc expression commenced with the appearance of morphologically identifiable mast cells in wk 3 and 4 (Fig. 1A) . In contrast, the ubiquitously expressed isoform, Mitf-a, was expressed from the beginning of culture and was maintained throughout differentiation. Mitf-mc, Mitf-e, and Mitf-a were also detected in primary BMMCs, intestinal mast cells, and the mast cell line, C57 (Fig.  1B) . The intestinal mast cells also expressed the heart isoform. The melanocyte and the heart isoforms were not detected in BMMCs or embryonic stem cell-derived mast cells. Interestingly, Mitf was detected from peritoneal mast cells with PCR primers to the common Mitf sequence (25) , but specific Mitf isoform expression was not found.
The Mitf-a and Mitf-mc isoforms differ only by their unique amino termini. Contiguous with these unique domains is the Bdomain, which is common to both isoforms. The Mitf-e isoform essentially harbors a truncated B domain at its amino terminus. All isoforms share the functional transactivation, DNA binding, and dimerization motifs (Fig. 1C) . Given our previous findings in vitro that suggested preferential gene target specificity between isoforms, we next addressed whether these isoforms regulated distinct biological functions in vivo.
Restoration of Mitf isoforms into Mitf
Ϫ/Ϫ mast cells Mitf-mc was previously shown to differentially activate gene target promoters when compared with Mitf-m in luciferase reporter assays (25) . This finding prompted the question of whether Mitf isoforms regulated distinct gene targets, and thus possessed distinct biologic functions in vivo. To address this question, we restored individual Mitf isoform expression into Mitf Ϫ/Ϫ primary mast cells with the pMMP-IRES-puro retrovirus as described in Material and Methods. We estimate that ϳ30% of cells were transduced. After 2-3 wk in culture with puromycin, stable selectants 
FIGURE 5. Microarray analysis of BMMCs expressing Mitf isoforms.
Gene sets that were up-regulated by individual Mitf isoforms compared with the vector control were identified by microarray analysis using the Affymetrix MOE430A chips, which contain probe sets for 22,223 genes. The Venn diagram shows the number of shared and unique gene sets regulated by the Mitf isoforms. Probe sets were annotated with the GeneSpring software. The shared genes (white) are listed in Table I . Unique gene sets are available in the supplemental material.
were expanded; these selectants sustained Mitf expression that was readily detectable by Western blot (Fig. 2) .
Mitf isoforms restore granular morphology of Mitf Ϫ/Ϫ mast cells
Mitf null mast cells display a number of phenotypic abnormalities. We have observed that BMMCs from Mitf Ϫ/Ϫ cultured in IL-3 and SCF are hypogranular. Differences in granularity can be appreciated by staining with toluidine blue and by measuring side scatter (SSC) with flow cytometry. High signal intensity detected by SSC indicates increased granularity. Mitf ϩ/ϩ mast cells display heterogeneity in the degree of granularity that can be demonstrated by morphologic assessment of toluidine blue staining as well as a wide range of signal by SSC measurements (Fig. 3, A and B) . In contrast, Mitf null mast cells are relatively hypogranular with less toluidine blue staining and low SSC signal. We examined the morphologic changes of Mitf Ϫ/Ϫ BMMCs expressing the individual Mitf isoforms, Mitf-mc, Mitf-e, and Mitf-a. By SSC analysis on flow cytometry, the heterogenous granular phenotype was restored by all Mitf isoforms. However, by toluidine blue staining, the granules appeared most prominent in cells expressing the Mitf-mc and Mitf-a isoforms. We also observed that the mast cells expressing the Mitf-e isoform were more adherent to the cell culture flask during culture (data not shown). In addition, a proportion of the cells expressing the Mitf-e was larger as demonstrated by an increase in cells with higher forward scatter signal.
Mitf isoforms rescue integrin-directed migration
Mitf
Ϫ/Ϫ mast cells display impaired adhesion to fibroblasts (42) . We examined the capacity for Mitf isoforms to restore integrindirected (haptotactic) binding to fibronectin. This function has been shown to be dependent on both SCF and the integrin ␣ 4 ␤ 1 (32) . Fig. 4 shows that Mitf ϩ/ϩ cells migrate and bind to fibronectin in the presence of SCF. In contrast, Mitf Ϫ/Ϫ mast cells do not migrate and bind to fibronectin despite SCF treatment. Expression of the Mitf-mc, Mitf-e, and Mitf-a isoforms restores this capacity for SCF-dependent haptotaxis. No significant difference was seen in the degree of haptotaxic function between isoforms. a Genes unique to individual isoforms grouped in functional categories using the EASE gene ontogeny software program.
demonstrates that a number of genes (57) were commonly upregulated by all isoforms. However, each of the individual Mitf isoforms also regulated a unique set of genes (104 genes for Mitf-a, 80 genes for Mitf-mc, and 52 genes for Mitf-e). The 57 genes commonly regulated by all three Mitf isoforms expressed in mast cells were grouped into classes based on function assigned by visual inspection and by the gene ontogeny tools that are part of the GeneSpring and the EASE software (39) (http:// david.niaid.nih.gov/david/ease.htm). This gene set comprises the transcriptome regulated by Mitf and represent both direct and indirect gene targets (Table I ). The largest group represented was proteases (8 genes), followed by cell surface receptors and transporters (7 genes). We also identified a large number of signaling molecules and cell adhesion proteins (6 genes each). Of this common set of 57 genes, 21 were confirmed to be up-regulated in Mitf ϩ/ϩ mast cells as well. Several of the genes within this list had been identified previously as Mitf target genes, including the proteases mMCP-4 (12), mMCP-5 (13), mMCP-6 (14), granzyme B (15), and the adhesion molecule, SgIGSF4 (16). However, a number of potential novel and physiologically significant genes were also identified including the proteases mMCP-2 and mMCP-8, the signaling molecules ribosomal S6 kinase (RSK), SLAP, the chemokine ligands C-C 2, 3, 7, and the platelet-derived growth factor ␣.
We identified unique, nonoverlapping gene sets that were regulated by each of the individual Mitf isoforms, Mitf-e, Mitf-mc, and Mitf-a. The functions of these genes were annotated using the EASE gene ontogeny software (39) and grouped by biological activity (Table II) . The largest categories of genes regulated by the two mast cell selective isoforms, Mitf-mc and Mitf-e, were those involved in cell growth and/or maintenance and protein metabolism. In contrast, the most abundant group regulated by the ubiquitously expressed Mitf-a isoform was comprised of genes involved in signal transduction. Visual inspection of the unique gene lists revealed some intriguing results. In the Mitf-e-expressing cells, the gene with the highest signal intensity was proliferin (223-fold increase). The function of proliferin is not well characterized, but it may play a role in hemopoietic stem cell expansion (43) . Its expression and role in mast cells has not been described. The second most abundant gene was histocompatibility 2, class II Ag A, ␣ (43-fold increase), which is involved in Ag presentation. In the gene list unique to Mitf-mc, the most highly expressed gene was the protease cathepsin G (supplemental material). We determined by quantitative PCR analysis that cathepsin G was also regulated by the other isoforms (Fig. 6 ), but to a lesser degree. We also found that the genes for myeloperoxidase, proteinase 3, and neutrophil elastase were on this list, which are genes that are commonly expressed in the neutrophil lineage. These gene sets are available in the supplemental material.
Validation of Mitf gene targets
We used quantitative real-time PCR to validate potential Mitf gene targets. We chose to examine a number of previously described targets as well as potentially novel and physiologically important gene targets that were identified in our microarray analysis. Given the fact that proteases comprised the largest group of genes regulated by Mitf isforms, we quantified the expression of the mMCPs as well as the protease cathepsin G and the previously identified Mitf target granzyme B (15) . We confirmed that the previously identified Mitf gene targets, mMCP-4, mMCP-5, mMCP-6, and granzyme B were up-regulated by all Mitf isoforms. However, we found that the potential novel targets, mMCP-1 and mMCP-2 also were up-regulated by all Mitf isoforms. In addition, two other proteases, mMCP-8 and cathepsin G, appeared to be selectively regulated by the mast cell-specific isoforms, Mitf-mc and Mitf-e (Fig. 6) .
We also examined the expression of RSK and SLAP, two signaling molecules that were identified by the microarray analysis as potential novel Mitf gene targets. Fig. 7A shows that the expression of both RSK and SLAP were up-regulated by all three Mitf isoforms, concurring with the microarray data. We also examined the expression of c-Kit, which had been identified previously as a potential Mitf target gene (44) . By quantitative PCR analysis, we found a 4-fold increase in expression between Mitf ϩ/ϩ and Mitf Ϫ/Ϫ mast cells, and that c-Kit expression was restored to wildtype levels only by Mitf-a expression in mast cells. This pattern of c-Kit expression was also correlated at the protein level by flow cytometry. Mitf Ϫ/Ϫ cells expressed c-Kit on their surface, but at a lower intensity compared with Mitf ϩ/ϩ mast cells. The Mitf-mc and Mitf-e cells expressed c-Kit at comparable levels to the Mitf Ϫ/Ϫ cells. In contrast, cells expressing Mitf-a restored c-Kit expression to wild-type levels (Fig. 7B) .
A number of genes encoding proteins that regulate cell adhesion were also identified by the microarray analysis, including SgIGSF4, a previously identified Mitf gene target (16) . Upon inspection of the genes common to the Mitf-mc and Mitf-e isoforms identified by microarray analysis, we also identified ␣ E integrin, another protein with a role in cell adhesion. Quantitative real-time PCR confirmed that both of these genes were up-regulated by all Mitf isoforms. Another protein important for the adhesion and migration of mast cells is the ␣ 4 integrin. This gene has previously been described to be a Mitf target in mast cells (17) , but we did not identify it in our microarray analysis. By quantitative PCR analysis, however, we found that ␣ 4 integrin mRNA was highly expressed in Mitf-mc and Mitf-e mast cells. In contrast, ␣ 4 integrin expression in Mitf-a was comparable to that of Mitf Ϫ/Ϫ cells (Fig.  8A) . In concurrence with the quantitative PCR analysis, ␣ 4 integrin was selectively expressed on the surface of the Mitf-mc and Mitf-e mast cells as assessed by flow cytometry for VLA4 (very late activation protein receptor 4, comprised of ␣ 4 and ␤ 1 subunits), whereas Mitf-a cells had no detectable levels of ␣ 4 integrin on their surface (Fig. 8B ).
Discussion
In this study, we report a comprehensive analysis of the function of the in vivo-expressed isoforms of the transcription factor, Mitf, in mast cells. The gene targets we identified define the mast cell Mitf transcriptome. Multiple, distinct, isoforms are expressed in mast cells and provide a mechanism for highly restricted, tissue-selective regulation of their expression; multiple isoforms also allow for redundancy in critical shared functions and diversity of unique functions. The major classes of genes regulated by Mitf in mast cells include proteases, cell surface receptors/transporters, signaling molecules, and cell adhesion proteins. These genes play roles in critical functions of the mast cell, and support the paradigm in which Mitf is a master regulator of mast cell differentiation.
We found that Mitf-a, Mitf-e, and Mitf-mc were the major isoforms detected from immature or "mucosal-type" mast cells (BMMC and intestinal mast cells). In contrast, peritoneal mast cells, which are phenotypically mature and represent "connective tissue-type" mast cells, did not express these isoforms by RT-PCR. These findings suggest that other isoform(s) are expressed in connective tissue-type mast cells, or that the expression of these Mitf isoforms were below the limits of detection in our PCR assay. The heart isoform was also detected from intestinal mast cells (Fig.  1B) ; we and others (22, 25, 41) have detected this isoform and other Mitf isoforms from mast cells. However, we found that Mitf-a, Mitf-e, and Mitf-mc were the most strongly and consistently expressed isoforms in the different mast cells types; therefore, we focused on these isoforms in this study.
We have found that Mitf regulates the expression of the two major classes of proteases in mast cells; the chymases and the tryptases. In rodents, the chymases include mMCP-1,-2, -4, -5, and -9, whereas the tryptases included mMCP-6 and mMCP-7. In addition, cathepsin G is a protease closely related to chymases (45) . mMCP-8 is a serine protease that is distinct from chymases and tryptases, but most closely resembles cathepsin G (46) . These mast cell proteases have been implicated in a wide variety of physiologic processes including inflammation, fibrosis, and wound healing. We validated previously identified Mitf targets, including mMCP-4, mMCP-5, mMCP-6, granzyme B, and cathepsin G. In addition, we have also found potential new targets, including mMCP-1, mMCP-2, mMCP-8, and tryptase ␥1.
The finding that signal transduction molecules are regulated by Mitf may provide insight into the basis of the poor response of Mitf Ϫ/Ϫ mast cells to SCF. Our screen identified RSK and SLAP as potential novel Mitf targets. We also confirmed the impaired expression of c-Kit in Mitf Ϫ/Ϫ mast cells, which had been described previously. RSK is known to function downstream of c-Kit signaling, and thus the deficient expression of both RSK and c-Kit in Mitf Ϫ/Ϫ cells may partly explain the lack of response to SCF stimulation. All Mitf isoforms restored the expression of RSK, but interestingly, only the ubiquitously expressed Mitf-a isoform restored c-Kit expression to wild-type levels. However, all Mitf isoforms were able to restore SCF-directed migration (haptotaxis assay). In addition, all Mitf isoforms restored SCF-induced proliferation as measured by colorimetric viability assays (3-(4,5-dimethylthiazol-2-2yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) to various degrees (data not shown). Thus, Mitf may regulate components of the signaling machinery required for SCF function. An alternative hypothesis to explain the defect in SCF response is that SCF signaling targets Mitf for phosphorylation and that SCF function may require Mitf phosphorylation. We have previously shown that SCF signaling targets Mitf in melanocytes (47) . Taken together, these findings support a model in which c-Kit signaling phosphorylates Mitf, and phosphorylated Mitf subsequently regulates the expression of c-Kit and other signaling molecules in a positive feedback loop.
We found several genes that were preferentially regulated by the relatively specific mast cell isoforms, Mitf-mc and Mitf-e. These included the proteases cathepsin G and mMCP-8, as well as the adhesion molecule ␣ 4 integrin (Figs. 6 and 8) . Analysis of the unique gene sets regulated by these two isoforms identified many genes involved in general biological processes such as cell growth and protein metabolism. Intriguingly, several neutrophil-specific genes were identified in the unique gene set of Mitf-mc, suggesting either a direct or indirect role for this isoform in regulating these genes (see supplemental material). We have not, however, found Mitf-mc expressed in neutrophil cell lines (A. H. Shahlaee, unpublished data). The unique gene list of the Mitf-e cells was not comprised of cellspecific genes; however, these cells did adhere to the culture flask with a morphologic appearance reminiscent of macrophages. In addition, histocompatibility class II Ag was one of the genes with the highest expression (42-fold; supplemental material), characteristic of APCs such as macrophages or dendritic cells. Although this study identified the genes regulated by individual Mitf isoforms, it is possible that the complete mast cell program regulated by Mitf requires the coexpression of these isoforms.
This analysis compared differentially expressed genes in the presence and absence of Mitf. However, a number of Mitf target genes have been identified that are selectively impaired by dominant-negative Mitf alleles, and not Mitf null alleles. This finding suggests that a set of Mitf gene targets requires Mitf protein partners. Thus, gene targets regulated preferentially by heterodimers of Mitf isoforms or those that require Mitf protein partners may not be identified in our analysis. The fact that isoforms regulated distinct gene sets in vivo suggests that their unique amino termini may mediate specific protein-protein interactions and/or may alter DNA-binding specificity. We have previously shown that the mast cell and melanocyte isoforms possess a differential capacity to activate promoters in reporter assays, but they can bind identical DNA sequences in vitro (25) . Thus, the amino-terminal domains may participate in the recruitment of protein complexes to the promoter. Further examination of the sequences of these promoters may provide insight into the mechanisms by which Mitf isoforms regulate these genes. Our previous analysis of Mitf target sequences revealed that DNA binding sites in melanocytes are distinct from those in mast cells (25) . However, inspection of the promoters of the genes identified in our study with known Mitf binding sites (c-Kit, ␣ 4 integrin, mMCP-4, -5, -6, granzyme B, and cathepsin G) did not reveal isoform-specific sequences.
Our experimental design identified genes up-regulated after several weeks of expression of Mitf, therefore determining both direct and indirect targets of Mitf. The verification of direct gene targets of Mitf will require further studies, such as chromatin immunoprecipitation, EMSAs, and reporter assays. We have found that the relative transactivation potential between Mitf isoforms when measured by reporter assays did not reliably correlate with expression determined by quantitative PCR. For example, we found that the Mitf-a, Mitf-mc, and Mitf-e isoforms have a comparable transactivation potential on the promoters for ␣ 4 integrin (17) and c-Kit (44) in luciferase assays (data not shown). In contrast, Figs. 7 and 8 suggest that these Mitf isoforms have a differential capacity to regulate these genes when expressed in vivo. This discrepancy highlights the many factors that may determine the genes identified on this screen, including the influence of chromatin structure, DNA methylation, other cell-specific coregulatory proteins that interact with Mitf, and the presence of distant enhancer or silencing elements; in vitro assays may not account for these factors. Taken together, these findings define the genetic program regulated by the physiologically expressed isoforms of Mitf, and suggest a central role for Mitf in directing the expression of a number of genes critical for the function and development of mast cells.
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